Drug Search Results
More Filters [+]

Belnacasan

Alternative Names: belnacasan, vx-765
Latest Update: 2024-09-06
Latest Update Note: Clinical Trial Update

Product Description

Belnacasan prevents the activation of a particular enzyme, Caspase-1, which plays a major role in activating this damaging immune response brought on by COVID-19. The goal of this medication being a more targeted treatment that aims to prevent the devastating immune response. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05164120)

Mechanisms of Action: CAAP Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Vertex
Company Location: BOSTON MA 02210
Company CEO: Reshma Kewalramani
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Belnacasan

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: COVID-19

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MedStar-COVID-19-belnacasan

P2

Completed

COVID-19

2022-07-18

Recent News Events